Handan He

3.0k total citations
54 papers, 1.8k citations indexed

About

Handan He is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Handan He has authored 54 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pharmacology, 18 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Handan He's work include Pharmacogenetics and Drug Metabolism (21 papers), Drug Transport and Resistance Mechanisms (10 papers) and Analytical Chemistry and Chromatography (9 papers). Handan He is often cited by papers focused on Pharmacogenetics and Drug Metabolism (21 papers), Drug Transport and Resistance Mechanisms (10 papers) and Analytical Chemistry and Chromatography (9 papers). Handan He collaborates with scholars based in United States, Switzerland and United Kingdom. Handan He's co-authors include Tycho Heimbach, J. Steven Richardson, Volker Fischer, Binfeng Xia, Rhys D.O. Jones, Tsu‐Han Lin, Abu T.M. Serajuddin, Hequn Yin, Christopher R. Gibson and M. Sherry Ku and has published in prestigious journals such as Cancer Research, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Handan He

54 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Handan He United States	26	591	485	411	281	280	54	1.8k
Trudy Rodgers United Kingdom	9	878 1.5×	749 1.5×	364 0.9×	154 0.5×	270 1.0×	12	2.0k
Don K. Walker United Kingdom	22	385 0.7×	309 0.6×	631 1.5×	135 0.5×	284 1.0×	40	2.2k
Christopher R. Gibson United States	17	731 1.2×	558 1.2×	418 1.0×	94 0.3×	273 1.0×	44	1.7k
Kevin B. Alton United States	26	501 0.8×	545 1.1×	691 1.7×	203 0.7×	139 0.5×	49	2.8k
Toshiro Niwa Japan	27	1.1k 1.8×	505 1.0×	452 1.1×	145 0.5×	128 0.5×	98	2.2k
Praveen Balimane United States	21	334 0.6×	952 2.0×	559 1.4×	299 1.1×	122 0.4×	34	2.1k
Chuang Lu United States	23	1.1k 1.9×	748 1.5×	659 1.6×	94 0.3×	305 1.1×	56	2.3k
Thierry Lavé Switzerland	35	1.3k 2.2×	1.1k 2.2×	682 1.7×	239 0.9×	485 1.7×	68	3.0k
Charles J. Rotter United States	17	367 0.6×	613 1.3×	474 1.2×	150 0.5×	219 0.8×	25	1.3k
K Rowland‐Yeo United Kingdom	16	702 1.2×	519 1.1×	285 0.7×	76 0.3×	150 0.5×	22	1.6k

Countries citing papers authored by Handan He

Since Specialization

Citations

This map shows the geographic impact of Handan He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Handan He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Handan He more than expected).

Fields of papers citing papers by Handan He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Handan He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Handan He. The network helps show where Handan He may publish in the future.

Co-authorship network of co-authors of Handan He

This figure shows the co-authorship network connecting the top 25 collaborators of Handan He. A scholar is included among the top collaborators of Handan He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Handan He. Handan He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, Handan & Jinzi J. Wu. (2023). Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist. Drugs in R&D. 23(4). 453–464. 3 indexed citations

Umehara, Kenichi, Felix Huth, Yi Jin, et al.. (2019). Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug Metabolism and Personalized Therapy. 34(2). 29 indexed citations

Einolf, Heidi J., Surya Ayalasomayajula, Tsu‐Han Lin, et al.. (2017). Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model. Journal of Pharmaceutical Sciences. 106(5). 1439–1451. 18 indexed citations

Gu, Helen, Catherine Dutreix, Sam Rebello, et al.. (2017). Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. Drug Metabolism and Disposition. 46(2). 109–121. 25 indexed citations

Heimbach, Tycho, Jay Prakash Jain, Rakesh Awasthi, et al.. (2016). A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric Patients. Journal of Pharmaceutical Sciences. 105(10). 3205–3213. 22 indexed citations

Zhang, Tao, et al.. (2015). Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds. Journal of Pharmaceutical Sciences. 104(9). 2795–2806. 47 indexed citations

Zhang, Hefei, Binfeng Xia, Jennifer Sheng, et al.. (2014). Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect. AAPS PharmSciTech. 15(2). 400–406. 29 indexed citations

Xia, Binfeng, et al.. (2013). A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy. The AAPS Journal. 15(4). 1012–1024. 54 indexed citations

Lin, Tsung‐Hsien, et al.. (2013). Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemotherapy and Pharmacology. 72(1). 181–188. 13 indexed citations

10.

Heimbach, Tycho, Binfeng Xia, Tsu‐Han Lin, & Handan He. (2012). Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data. The AAPS Journal. 15(1). 143–158. 46 indexed citations

11.

Xia, Binfeng, Tycho Heimbach, Tsu‐Han Lin, et al.. (2012). Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions. Cancer Chemotherapy and Pharmacology. 69(6). 1567–1582. 21 indexed citations

12.

Jones, Rhys D.O., Hannah M. Jones, Malcolm Rowland, et al.. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution. Journal of Pharmaceutical Sciences. 100(10). 4074–4089. 104 indexed citations

13.

Poulin, Patrick, Rhys D.O. Jones, Hannah M. Jones, et al.. (2011). PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach. Journal of Pharmaceutical Sciences. 100(10). 4127–4157. 132 indexed citations

14.

Vuppugalla, Ragini, Punit Marathe, Handan He, et al.. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach. Journal of Pharmaceutical Sciences. 100(10). 4111–4126. 49 indexed citations

15.

Heimbach, Tycho, Suresh B. Lakshminarayana, Wenyu Hu, & Handan He. (2009). Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data. The AAPS Journal. 11(3). 602–14. 24 indexed citations

16.

He, Handan, Hequn Yin, Harold T. Smith, et al.. (2008). Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans. Drug Metabolism and Disposition. 37(3). 536–544. 119 indexed citations

17.

He, Handan, Hequn Yin, Harold T. Smith, et al.. (2008). Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs. Drug Metabolism and Disposition. 37(3). 545–554. 25 indexed citations

18.

Li, Wenkui, et al.. (2007). Determination of N‐methyl‐4‐isoleucine‐cyclosporin (NIM811) in human whole blood by high performance liquid chromatography‐tandem mass spectrometry. Biomedical Chromatography. 21(3). 249–256. 4 indexed citations

19.

He, Handan, et al.. (1995). Development and Application of a Specific and Sensitive Radioimmunoassay for Trihexyphenidyl to a Pharmacokinetic Study in Humans. Journal of Pharmaceutical Sciences. 84(5). 561–567. 10 indexed citations

20.

He, Handan, G. McKay, & K.K. Midha. (1995). Phase I and II metabolites of benztropine in rat urine and bile. Xenobiotica. 25(8). 857–872. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact